Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

208
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
208
Clinical Trials01:16

Clinical Trials

7.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.8K
Depression: Overview01:18

Depression: Overview

331
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
331
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same author

Design of Trials with Composite Endpoints with the R Package CompAREdesign.

Statistics in biosciences·2026
Same author

On the Inclusion of Non-Concurrent Controls in Platform Trials With an Interim Analysis.

Statistics in medicine·2026
Same author

A Pilot Study to Explore Length and Readability Characteristics of Subject Information Sheets/Informed Consent Forms of Clinical Trial Applications in the EU.

Clinical and translational science·2026
Same author

When randomization is not random: Allocation bias in small sample, group sequential randomized clinical trials.

Statistical methods in medical research·2026
Same author

A Novel Approach to the Design and Sample Size Planning of Animal Experiments Based on Effect Estimation.

Biometrical journal. Biometrische Zeitschrift·2026

Related Experiment Video

Updated: Sep 10, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.5K

Design Considerations for a Phase II Platform Trial in Major Depressive Disorder.

Michaela Maria Freitag1, Dario Zocholl1,2, Elias Laurin Meyer3,4

  • 1Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Pharmaceutical Statistics
|August 27, 2025
PubMed
Summary
This summary is machine-generated.

Platform trials accelerate the development of new treatments for major depressive disorder (MDD) by efficiently evaluating multiple therapies simultaneously. These trials demonstrate higher statistical power and efficiency, especially with early stopping rules for ineffective treatments.

Keywords:
allocationclinical trial simulationsfutility stoppingmajor depressive disordermultiple treatment armsplatform trial

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

791
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K

Related Experiment Videos

Last Updated: Sep 10, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.5K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

791
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K

Area of Science:

  • Clinical trial design
  • Pharmacoeconomics
  • Psychiatry

Background:

  • Major depressive disorder (MDD) is a leading global cause of disability, with many patients unresponsive to current treatments.
  • Limited recent drug development necessitates more efficient evaluation methods for novel therapeutic options.

Purpose of the Study:

  • To support the design and optimization of a Phase II superiority platform trial for MDD.
  • To assess the efficiency of platform trials versus traditional two-arm trials for MDD treatments.

Main Methods:

  • Conducted extensive simulations to evaluate key design elements: allocation, randomization, sample size, and interim futility analyses.
  • Compared the performance of platform trials against traditional two-arm trial designs.

Main Results:

  • Platform trials enhance efficiency and achieve higher statistical power for evaluating individual MDD treatments compared to conventional trials.
  • Interim futility analyses significantly improve platform trial efficiency by early elimination of ineffective treatments.

Conclusions:

  • Platform trials offer a flexible and powerful alternative to traditional designs for accelerating MDD therapy development.
  • Optimized platform trial designs, incorporating futility analyses, are crucial for efficient drug evaluation in MDD and other conditions.